Confidence Inc. Issues a Voluntary Nationwide Recall in the United
States and Canada of One Lot of METABOSLIM Apple Cider Vinegar brand
dietary supplement found to contain an Undeclared Drug Ingredient
Contact:
Confidence Inc.
516-767-1870
FOR IMMEDIATE RELEASE --Port Washington, NY -- August 17, 2007 ---
Confidence Inc. of Port Washington, NY, is recalling one lot of
METABOSLIMTM Apple Cider Vinegar brand dietary supplement, lot number
3001006, EXP. 102009 and UPC CODE: 92483 00102 because it contains the
undeclared drug ingredient sibutramine. This lot was primarily sold in
Canada. The product is sold in a plastic bottle with white and red
labeling and contains 60 gelatin capsules.
The Company has been informed by the Food and Drug Administration (FDA)
that lab analysis of METABOSLIMTM samples found that the product
contains undeclared sibutramine, an FDA approved drug used as an
appetite suppressant for weight loss. The FDA has not approved
METABOSLIMTM as a drug; therefore the safety and effectiveness of this
product is unknown.
FDA advises that this poses a threat to consumers because sibutramine is
known to substantially increase blood pressure and/or pulse rate in some
patients and may present a significant risk for patients with a history
of coronary artery disease, congestive heart failure, arrhythmias or
stroke.
No illnesses or injuries have been reported to the company to date in
connection with this product.
Confidence, Inc. has taken this voluntary action because it is committed
to providing accurate information about its products and because of the
concern for the health and safety of consumers. Confidence Inc. is
working with the FDA in the recall process. It sincerely regrets any
inconvenience to customers.
Consumers should return any unused METABOSLIMTM for a refund of the full
purchase price or price for the unused portion, to the Company's address
in Port Washington, NY, or contact Jim Chao at 516-767-1870 or email
jim@confidenceusa.com to receive further instructions for returning the
product or with any questions.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment